J 
Jamjoom Pharmaceuticals Factory Company SJSC 4015.SR · SAR
Health Care · Tadawul · 🇸🇦 Saudi Arabia
112.80
—
Close of 9 Nov 2026, in SAR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in SAR, from our data supplier.
Revenue
SAR 1.50bn
FY2018FY2025
Net income
SAR 463.8m
FY2018FY2025
Free cash flow
SAR 332.0m
FY2018FY2025
Shareholders' equity
SAR 1.72bn
FY2018FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | SAR 1.50bn | SAR 1.32bn | SAR 1.10bn | SAR 916.7m | SAR 735.7m | SAR 805.3m | SAR 731.7m | SAR 701.3m |
| Gross profit | SAR 938.8m | SAR 820.5m | SAR 701.7m | SAR 593.9m | SAR 474.7m | SAR 513.3m | SAR 419.4m | SAR 438.3m |
| Research and development | SAR 38.7m | SAR 34.0m | SAR 33.4m | SAR 32.7m | SAR 37.0m | SAR 36.5m | — | — |
| Operating income | SAR 474.8m | SAR 381.1m | SAR 315.9m | SAR 233.3m | SAR 189.9m | SAR 248.1m | SAR 174.5m | SAR 171.9m |
| Net income | SAR 463.8m | SAR 356.5m | SAR 292.4m | SAR 171.3m | SAR 170.7m | SAR 206.9m | SAR 156.9m | SAR 150.8m |
| Diluted earnings per share | 6.81 | 5.09 | 4.18 | 2.45 | 2.44 | 2.96 | 2.24 | 2.15 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Total assets | SAR 2.05bn | SAR 1.77bn | SAR 1.65bn | SAR 1.41bn | SAR 1.43bn | SAR 1.50bn | SAR 1.28bn | SAR 1.21bn |
| Cash and short-term investments | — | SAR 262.3m | SAR 289.4m | SAR 146.3m | SAR 113.2m | SAR 235.7m | SAR 199.5m | SAR 175.3m |
| Total liabilities | SAR 328.8m | SAR 281.0m | SAR 249.8m | SAR 191.6m | SAR 200.7m | SAR 316.6m | SAR 214.1m | SAR 207.5m |
| Debt | — | SAR 2.1m | SAR 2.4m | SAR 2.6m | SAR 7.1m | SAR 99.4m | SAR 16.3m | SAR 14.0m |
| Shareholders' equity | SAR 1.72bn | SAR 1.49bn | SAR 1.40bn | SAR 1.22bn | SAR 1.23bn | SAR 1.18bn | SAR 1.07bn | SAR 999.8m |
| Shares outstanding | 68m | 70m | 70m | 70m | 70m | 70m | 70m | 70m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | SAR 406.3m | SAR 263.3m | SAR 296.0m | SAR 229.2m | SAR 228.7m | SAR 261.9m | SAR 203.6m | SAR 112.7m |
| Capital spending | −SAR 74.3m | −SAR 57.0m | −SAR 45.8m | −SAR 87.7m | −SAR 126.8m | −SAR 163.6m | −SAR 71.0m | −SAR 47.0m |
| Free cash flow | SAR 332.0m | SAR 206.3m | SAR 250.3m | SAR 141.6m | SAR 101.9m | SAR 98.3m | SAR 132.6m | SAR 65.8m |
| Dividends paid | −SAR 242.2m | −SAR 217.0m | −SAR 70.0m | −SAR 148.8m | −SAR 113.3m | −SAR 90.7m | −SAR 86.0m | −SAR 100.0m |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | SAR 445.3m | SAR 481.4m | SAR 304.6m | SAR 342.3m | SAR 396.2m | SAR 457.5m | SAR 259.7m | SAR 327.6m |
| Gross profit | SAR 293.7m | SAR 310.4m | SAR 186.6m | SAR 206.3m | SAR 250.8m | SAR 292.9m | SAR 158.5m | SAR 194.4m |
| Operating income | SAR 145.1m | SAR 175.5m | SAR 148.2m | SAR 108.2m | SAR 135.3m | SAR 158.2m | SAR 54.6m | SAR 95.7m |
| Net income | SAR 137.6m | SAR 168.2m | SAR 68.1m | SAR 106.7m | SAR 132.0m | SAR 157.0m | SAR 51.6m | SAR 95.0m |
| Diluted earnings per share | 1.97 | 2.40 | 1.00 | 1.57 | 1.94 | 2.31 | 0.74 | 1.36 |
| Cash from operations | SAR 76.0m | SAR 1.0m | SAR 200.0m | SAR 140.0m | SAR 70.0m | −SAR 6.0m | SAR 153.0m | SAR 87.0m |
| Capital spending | −SAR 20.0m | −SAR 6.0m | −SAR 30.0m | −SAR 13.0m | −SAR 15.0m | −SAR 11.0m | −SAR 10.0m | −SAR 10.0m |
| Free cash flow | SAR 56.0m | −SAR 5.0m | SAR 170.0m | SAR 127.0m | SAR 55.0m | −SAR 17.0m | SAR 143.0m | SAR 77.0m |
| Total assets | SAR 2.34bn | SAR 2.11bn | SAR 2.05bn | SAR 2.05bn | SAR 2.08bn | SAR 1.90bn | SAR 1.77bn | SAR 1.86bn |
| Cash and short-term investments | — | — | — | SAR 169.7m | SAR 183.9m | SAR 138.1m | SAR 262.3m | SAR 121.8m |
| Debt | — | — | — | SAR 774,820 | SAR 763,477 | SAR 549,016 | SAR 523,682 | SAR 518,275 |
| Shareholders' equity | SAR 1.88bn | SAR 1.73bn | SAR 1.72bn | SAR 1.65bn | SAR 1.68bn | SAR 1.55bn | SAR 1.49bn | SAR 1.44bn |
Financial ratios
Data as of 7 Oct 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|
| Gross margin | 62.6% | 62.2% | 63.7% | 64.8% | 64.5% | 63.7% | — |
| Operating margin | 32.9% | 29.0% | 28.7% | 20.3% | 25.6% | 29.7% | — |
| Net margin | 30.9% | 27.0% | 26.6% | 18.7% | 23.2% | 25.7% | — |
| Return on equity | 27.0% | 23.9% | 20.8% | 14.1% | 13.9% | 17.5% | — |
| Return on assets | 22.7% | 20.1% | 17.7% | 12.2% | 11.9% | 13.8% | — |
| Free cash flow yield | 5.5% | 3.5% | 3.8% | 3.5% | 3.9% | — | — |
| Revenue growth | 13.8% | 19.8% | 20.1% | 24.6% | -8.6% | 10.1% | — |
| Earnings growth | 30.1% | 21.9% | 70.7% | 0.4% | -17.5% | 31.8% | — |
| Current ratio | 5.53x | 5.10x | 5.04x | 5.42x | 5.06x | 3.54x | — |
| Debt to equity | — | 0.00x | 0.00x | -0.00x | 0.01x | 0.08x | 0.02x |
| Equity ratio | 83.9% | 84.1% | 84.9% | 86.4% | 86.0% | 78.8% | — |
| Interest coverage | 2561.88x | 3772.69x | 503.67x | 1524.92x | 59.15x | — | — |
| R&D as a share of sales | 2.6% | 2.6% | 3.0% | 3.6% | 5.0% | 4.5% | — |
| Buybacks as a share of market value | 2.7% | 0.0% | 0.0% | 0.0% | — | — | — |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 17.9% | 13.3% | — |
| Operating income | 26.7% | 13.9% | — |
| Net income | 39.4% | 17.5% | — |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 62.4% | 63.2% | 63.4% | — |
| Operating margin | 30.4% | 29.1% | 28.9% | — |
| Net margin | 29.1% | 26.5% | 26.1% | — |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Price to earnings | 20.9 | 29.9 | 27.5 |
| Price to sales | 6.5 | 8.1 | 7.3 |
Dividends and splits
Per share, in the currency the company pays
Paid for 3 years. Last went ex-dividend on 2 Aug 2026.
| FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Paid in the year | 4.20 | 3.46 | 3.10 | 1.00 |
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.